Increased levels of circulating soluble CD14 but not CD83 in infants are associated with early intestinal colonization with Staphylococcus aureus

Clinical and Experimental Allergy

Volumn 37, Issue 1, 2007, Pages 62-71

  Lundell, A C ^a   Adlerberth, I ^a   Lindberg, E ^a   Karlsson, H ^a   Ekberg, S ^a   Aberg N ^a   Saalman, R ^a   Hock, B ^b   Steinkasserer, A ^c   Hesselmar, B ^a   Wold, A E ^a   Rudin, A ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Infants; Intestinal commensal bacteria; Soluble CD14; Soluble CD83; Staphylococcus aureus

Indexed keywords

CD14 ANTIGEN; CD83 ANTIGEN; IMMUNOGLOBULIN E;

AEROBIC BACTERIUM; ALLERGY; ANAEROBIC BACTERIUM; ARTICLE; BACTERIAL COLONIZATION; BACTEROIDES; BIFIDOBACTERIACEAE; CLOSTRIDIA; COHORT ANALYSIS; CONTROLLED STUDY; ENTEROBACTER; ENTEROCOCCACEAE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FECES ANALYSIS; FECES MICROFLORA; FEMALE; HUMAN; INFANT; INTESTINE FLORA; LACTOBACILLUS; MALE; NONHUMAN; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE; SWEDEN;

ANTIGENS, CD; ANTIGENS, CD14; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FOOD HYPERSENSITIVITY; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULINS; INFANT, NEWBORN; INTESTINES; LONGITUDINAL STUDIES; MALE; MEMBRANE GLYCOPROTEINS; STAPHYLOCOCCUS AUREUS; STATISTICS, NONPARAMETRIC;

EID: 33845772188     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02625.x     Document Type: Article

References (40)

1. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299:1259-60.
2. Braun-Fahrlander C, Riedler J, Herz U et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002; 347:869-77.
3. Bottcher MF, Bjorksten B, Gustafson S, Voor T, Jenmalm MC. Endotoxin levels in Estonian and Swedish house dust and atopy in infancy. Clin Exp Allergy 2003; 33:295-300.
4. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-7.
5. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-3.
6. Dziarski R, Tapping RI, Tobias PS. Binding of bacterial peptidoglycan to CD14. J Biol Chem 1998; 273:8680-90.
7. Durieux JJ, Vita N, Popescu O et al. The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol 1994; 24:2006-12.
8. Labeta MO, Vidal K, Nores JE et al. Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med 2000; 191:1807-12.
9. Berner R, Furll B, Stelter F, Drose J, Muller HP, Schutt C. Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis. Clin Diagn Lab Immunol 2002; 9:440-5.
10. Yu S, Nakashima N, Xu BH et al. Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: in the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatol Int 1998; 17:237-43.
11. Rey Nores JE, Bensussan A, Vita N et al. Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur J Immunol 1999; 29:265-76.
12. Arias MA, Rey Nores JE, Vita N et al. Cutting edge human B cell function is regulated by interaction with sCD14: opposite effects on IgG1 and IgE production. J Immunol 2000; 164:3480-6.
13. Zhou LJ, Schwarting R, Smith HM, Tedder TF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol 1992; 149:735-42.
14. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
15. Hock BD, Kato M, McKenzie JL, Hart DN. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int Immunol 2001; 13:959-67.
16. Kotzor N, Lechmann M, Zinser E, Steinkasserer A. The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells. Immunobiology 2004; 209:129-40.
17. Lechmann M, Krooshoop DJ, Dudziak D et al. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med 2001; 194:1813-21.
18. Zinser E, Lechmann M, Golka A, Lutz MB, Steinkasserer A. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J Exp Med 2004; 200:345-51.
19. Zdolsek HA, Jenmalm MC. Reduced levels of soluble CD14 in atopic children. Clin Exp Allergy 2004; 34:532-9.
20. Lindberg E, Nowrouzian F, Adlerberth I, Wold AE. Long-time persistence of superantigen-producing Staphylococcus aureus strains in the intestinal microflora of healthy infants. Pediatr Res 2000; 48:741-7.
21. Adlerberth I, Lindberg E, Aberg N et al. Reduced enterobacterial and increased staphylococcal colonization of the infantile bowel: an effect of hygienic lifestyle? Pediatr Res 2006; 59:96-101.
22. Ahrne S, Nobaek S, Jeppsson B, Adlerberth I, Wold AE, Molin G. The normal Lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol 1998; 85:88-94.
23. Williams HC. Diagnostic criteria for atopic dermatitis. Lancet 1996; 348:1391-2.
24. Position paper: Allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology. Allergy 1993; 48 (14 Suppl.):48-82.
25. Karlsson H, Hessle C, Rudin A. Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. Infect Immun 2002; 70:6688-96.
26. Hock BD, Haring LF, Steinkasserer A, Taylor KG, Patton WN, McKenzie JL. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res 2004; 28:237-41.
27. Riedler J, Braun-Fahrlander C, Eder Wet al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001; 358:1129-33.
28. Lauener RP, Birchler T, Adamski J et al. Expression of CD14 and Toll-like receptor 2 in farmers' and non-farmers' children. Lancet 2002; 360:465-6.
29. Fournier B, Philpott DJ. Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev 2005; 18:521-40.
30. Gomez MI, Lee A, Reddy B et al. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat Med 2004; 10:842-8.
31. Van Camp JM, Tomaselli V, Coran AG. Bacterial translocation in the neonate. Curr Opin Pediatr 1994; 6:327-33.
32. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991; 147:1567-74.
33. Bufler P, Stiegler G, Schuchmann M et al. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur J Immunol 1995; 25:604-10.
34. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. J Immunol 2004; 172:4470-9.
35. Dudziak D, Nimmerjahn F, Bornkamm GW, Laux G. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol 2005; 174:6672-6.
36. Rescigno M, Urbano M, Valzasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2:361-7.
37. Hock BD, O'Donnell JL, Taylor K et al. Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients. Tissue Antigens 2006; 67:57-60.
38. Tan CY, Chen YL, Wu LS, Liu CF, Chang WT, Wang JY. Association of CD14 promoter polymorphisms and soluble CD14 levels in mite allergen sensitization of children in Taiwan. J Hum Genet 2006; 51:59-67.
39. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357:1076-9.
40. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361:1869-71.